EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer

Shihao Ning iD, Huiming Wu, Renkai Guo, Min Deng, Yipeng Cui, Dingwen Xue, Chunchen Li, Chenfei Jin, Huiyu Li

Cancer Control · 19.02.2026 · 33

DOI: 10.1177/10732748261430581 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Control, online erschienen am 02.03.2026. Verfasst von Shihao Ning und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Shanxi Bethun…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tumor-Associated Macrophages, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key Research and Development (R&D) Projects of Shanxi Province, Fundamental Research Program of Shanxi Province, Shanxi Province “136 Revitalization Medical Project Construction Funds”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related mortality worldwide. Currently, surgical resection remains the cornerstone of curative treatment for CRC; however, patients with advanced disease continue to face significant risks of postoperative recurrence and metastasis. Although immune checkpoint inhibitors (ICIs), represented by PD-1/PD-L1 monoclonal antibodies, have reshaped the therapeutic landscape of various solid tumors, their clinical benefit in CRC is strictly limited by mismatch repair (MMR) status, leaving the vast majority of proficient mismatch repair/microsatellite stable (pMMR/MSS) patients with minimal therapeutic gain. Importantly, tumor-associated macrophages (TAMs)—a key regulatory component of the tumor immune microenvironment—not only exert immunosuppressive functions through PD-1 and multiple other pathways, but also promote PD-1 expression on tumor cells via distinct mechanisms. Consequently, accumulating evidence suggests that TAMs play a critical role in mediating resistance to PD-1/PD-L1 inhibitors in CRC. Nevertheless, research on the underlying mechanisms remains at an early stage. This narrative review aims to summarize the latest advances regarding the involvement of TAMs in resistance to PD-1/PD-L1 blockade, with a particular focus on strategies to enhance immunotherapy responsiveness through TAM modulation. We further discuss limitations in current clinical studies and propose potential directions for future research. By juxtaposing successful mechanistic studies with underwhelming clinical trial data, we aim to redefine the therapeutic rationale for combining TAM-targeted agents with immune checkpoint blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTumor-Associated MacrophagesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 AntigenHumansTumor Microenvironment

Stichwörter der Autor:innen

colorectal neoplasmsimmune checkpoint inhibitorsimmune checkpoint proteinsmacrophagestumor microenvironment

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 AntigenPDCD1 protein, humanCD274 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Taiyuan, Shanxi, China.

ORCID-Profile: Shihao Ning

Förderung

  • Key Research and Development (R&D) Projects of Shanxi Province
  • Fundamental Research Program of Shanxi Province
  • Shanxi Province “136 Revitalization Medical Project Construction Funds”

Zitieren

APA

Ning, S., Wu, H., Guo, R., Deng, M., Cui, Y., Xue, D., Li, C., Jin, C., & Li, H. (2026). Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer. Cancer Control, 33. https://doi.org/10.1177/10732748261430581

Vancouver

Ning S, Wu H, Guo R, Deng M, Cui Y, Xue D, et al. Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer. Cancer Control. 2026;33. doi:10.1177/10732748261430581

BibTeX
@article{Ning2026,
  author = {Ning, Shihao and Wu, Huiming and Guo, Renkai and Deng, Min and Cui, Yipeng and Xue, Dingwen and Li, Chunchen and Jin, Chenfei and Li, Huiyu},
  title = {Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer},
  journal = {Cancer Control},
  year = {2026},
  volume = {33},
  doi = {10.1177/10732748261430581}
}
Kostenlos starten →